Effect of albiglutide on cardiovascular outcomes in older adults: A post hoc analysis of a randomized controlled trial

Matthew P. Gilbert,Joan Skelly,Adrian F. Hernandez,Jennifer B. Green,Konstantin A. Krychtiuk,Christopher B. Granger,Lawrence A. Leiter,John J. V. McMurray,Stefano Del Prato,Richard E. Pratley

DOI: https://doi.org/10.1111/dom.15479

2024-02-07

Diabetes Obesity and Metabolism

Abstract:Aim To analyse the effects of albiglutide, a glucagon‐like peptide 1 receptor agonist, on cardiovascular outcomes in older adults aged ≥65 years with type 2 diabetes and cardiovascular disease who participated in the Harmony Outcomes trial (NCT02465515). Materials and methods We conducted a post hoc analysis of the primary endpoint of the Harmony Outcomes trial—time to first occurrence of a major adverse cardiovascular event—in subgroups of participants aged <65 and ≥65 years and <75 and ≥75 years at baseline. Hazard ratios and 95% confidence intervals (CIs) were generated using Cox proportional hazards regression. Results The analysis population included 9462 Harmony Outcomes participants, including 4748 patients ≥65 and 1140 patients ≥75 years at baseline. Hazard ratios for the prevention of major adverse cardiovascular events were 0.66 (95% CI, 0.53‐0.82) in persons <65 and 0.86 (95% CI, 0.71‐1.04) in those ≥65 years (age interaction p = .07), and 0.78 (95% CI, 0.67‐0.91) in <75 and 0.70 (95% CI, 0.48‐1.01) in ≥75 year age groups (interaction p = .6). When analysed as a continuous variable, age did not modify the effect of albiglutide on the primary endpoint. Conclusions This post hoc analysis adds to the body of literature showing that glucagon‐like peptide 1 receptor agonists added to standard type 2 diabetes therapy safely reduce the incidence of cardiovascular events in older adults with established cardiovascular disease. In this analysis, the risk‐benefit profile was similar between younger and older age groups treated with albiglutide.

endocrinology & metabolism